Galmed Pharmaceuticals
GLMD
10 hedge funds and large institutions have $102K invested in Galmed Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0.25% less ownership
Funds ownership: 0.42% → 0.17% (-0.25%)
9% less funds holding
Funds holding: 11 → 10 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
27% less capital invested
Capital invested by funds: $140K → $102K (-$38.2K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$81.1K |
| 2 |
Two Sigma Investments
New York
|
+$34K |
| 3 |
WANY
Wealthspire Advisors (New York)
New York
|
+$39 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$53.8K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$42.7K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$19K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.55K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
-$3.38K |
GLMD Hedge Fund Activity: Q3 2025 in Review
10 of the 7,635 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2025, worth a combined $102K — down 27% from $140K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GLMD and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 0 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $81.1K. The largest seller was Morgan Stanley, cutting an estimated $53.8K.
- 10 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2025, down from 11 in Q2 2025.
- Funds reported $102K of Galmed Pharmaceuticals stock for Q3 2025, down 27% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q3 2025 and 4 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2025 was Citadel Advisors, an estimated $81.1K added.
- The largest Galmed Pharmaceuticals seller in Q3 2025 was Morgan Stanley, an estimated $53.8K sold.
Based on aggregated 13F filings for Q3 2025.